98 related articles for article (PubMed ID: 3934802)
41. In vitro characterization of various factor VIII concentrates.
Yoshioka A; Shima M; Nishino M; Yoshikawa N; Fukui H
Arzneimittelforschung; 1987 Jul; 37(7):753-6. PubMed ID: 3118888
[TBL] [Abstract][Full Text] [Related]
42. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.
Santagostino E; Mannucci PM; Gringeri A; Azzi A; Morfini M; Musso R; Santoro R; Schiavoni M
Transfusion; 1997 May; 37(5):517-22. PubMed ID: 9149778
[TBL] [Abstract][Full Text] [Related]
43. Viral safety of a new highly purified factor VIII (OCTATE).
Biesert L; Lemon S; Goudeau A; Suhartono H; Wang L; Brede HD
J Med Virol; 1996 Apr; 48(4):360-6. PubMed ID: 8699169
[TBL] [Abstract][Full Text] [Related]
44. Impact of residual moisture and formulation on Factor VIII and Factor V recovery in lyophilized plasma reference materials.
Hubbard A; Bevan S; Matejtschuk P
Anal Bioanal Chem; 2007 Apr; 387(7):2503-7. PubMed ID: 17072599
[TBL] [Abstract][Full Text] [Related]
45. Virus inactivation by pepsin treatment at pH 4 of IgG solutions: factors affecting the rate of virus inactivation.
Omar A; Kempf C; Immelmann A; Rentsch M; Morgenthaler JJ
Transfusion; 1996 Oct; 36(10):866-72. PubMed ID: 8863772
[TBL] [Abstract][Full Text] [Related]
46. [Comparative study of concentrated blood derivatives of factor VIII].
Baklaja R; Miletić V; Stajić M; Cvetković V; Grozdanić V
Bilt Hematol Transfuz; 1984; 12(2):91-103. PubMed ID: 6441567
[TBL] [Abstract][Full Text] [Related]
47. Characteristics of the von Willebrand factor in virus inactivated F VIII concentrates: the impact of heat treatment.
Ingerslev J; Bukh A; Wallevik K; Møller NP; Stenbjerg S
Thromb Res; 1987 Jul; 47(2):175-82. PubMed ID: 3116714
[TBL] [Abstract][Full Text] [Related]
48. Thermal inactivation of human immunodeficiency virus in lyophilised blood products evaluated by ID50 titrations.
Tersmette M; de Goede RE; Over J; de Jonge E; Radema H; Lucas CJ; Huisman HG; Miedema F
Vox Sang; 1986; 51(3):239-43. PubMed ID: 3643679
[TBL] [Abstract][Full Text] [Related]
49. Heat inactivation of human immunodeficiency virus in solutions of antithrombin III.
Einarsson M; Perenius L; McDougal JS; Cort S
Transfusion; 1989 Feb; 29(2):148-52. PubMed ID: 2919425
[TBL] [Abstract][Full Text] [Related]
50. Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue.
Wagner SJ; Skripchenko A; Robinette D; Mallory DA; Cincotta L
Transfusion; 1998 Aug; 38(8):729-37. PubMed ID: 9709780
[TBL] [Abstract][Full Text] [Related]
51. The effect of stabilizers and denaturants on the cold denaturation temperatures of proteins and implications for freeze-drying.
Tang XC; Pikal MJ
Pharm Res; 2005 Jul; 22(7):1167-75. PubMed ID: 16028018
[TBL] [Abstract][Full Text] [Related]
52. Chikungunya virus and the safety of plasma products.
Leydold SM; Farcet MR; Kindermann J; Modrof J; Pölsler G; Berting A; Howard MK; Barrett PN; Kreil TR
Transfusion; 2012 Oct; 52(10):2122-30. PubMed ID: 22339168
[TBL] [Abstract][Full Text] [Related]
53. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.
McDougal JS; Martin LS; Cort SP; Mozen M; Heldebrant CM; Evatt BL
J Clin Invest; 1985 Aug; 76(2):875-7. PubMed ID: 2993366
[TBL] [Abstract][Full Text] [Related]
54. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
Schwinn H; Smith A; Wolter D
Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
[TBL] [Abstract][Full Text] [Related]
55. Factor VIII concentrates made in the United Kingdom and the treatment of haemophilia based on studies made during 1969--72. Report of the Medical Research Council's Blood Transfusion Research Committee Working Party on the cryoprecipitate method of preparing AHF concentrates.
Br J Haematol; 1974 Jul; 27(3):391-405. PubMed ID: 4413414
[No Abstract] [Full Text] [Related]
56. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
[TBL] [Abstract][Full Text] [Related]
57. Inactivation of hepatitis A virus in plasma products by vapor heating.
Barrett PN; Meyer H; Wachtel I; Eibl J; Dorner F
Transfusion; 1997 Feb; 37(2):215-20. PubMed ID: 9051099
[TBL] [Abstract][Full Text] [Related]
58. Preparation of antihemophilic factor and fibronectin from human plasma cryoprecipitate.
Horowitz B; Lippin A; Chang MY; Shulman RW; Vandersande J; Stryker MH; Woods KR
Transfusion; 1984; 24(4):357-62. PubMed ID: 6431661
[TBL] [Abstract][Full Text] [Related]
59. Sterilisation of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate.
Prince AM; Horowitz B; Brotman B
Lancet; 1986 Mar; 1(8483):706-10. PubMed ID: 2870224
[TBL] [Abstract][Full Text] [Related]
60. Heat inactivation of human immunodeficiency virus in lyophilized anti-inhibitor coagulant complex (Autoplex).
Piszkiewicz D; Thomas W; Lieu M; Cabradilla CD; Andrews J; Kim J; Bourret E; McDougal JS; Cort SP
Thromb Res; 1986 Dec; 44(5):701-7. PubMed ID: 3492776
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
